1-20 of 253 results for subject:Methadone
Librarians' tools
- Search time
- 0.353 seconds
- Solr query time
- 0.003 seconds
- Search query
- subject:Methadone
- We searched for
- subject_t:Methadone OR subject_ses:297140
Type
House
Session
Year
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask His Majesty's Government what was the cost to the NHS of prescribing the heroine substitute drug methodone in (1) 2005, (2) 2010, (3) 2015, and (4) 2020.
To ask His Majesty's Government what was the cost to the NHS of prescribing the heroine substitute drug methodone in (1) 2005, (2) 2010, (3) 2015, and (4) 2020.
Information on the cost to the NHS of prescribing methadone is not held centrally.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 July 2020 to Question 61461 and the Answer of 18 August to Question 74489 on Methadone: Prescriptions, what recent assessment his Department has made of the capacity of prescribers to safely electronically prescribe...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 July 2020 to Question 61461 and the Answer of 18 August to Question 74489 on Methadone: Prescriptions, what recent assessment his Department has made of the capacity of prescribers to safely electronically prescribe...
In 2018 NHS Digital undertook a prioritisation exercise to identify future enhancements and improvements to the electronic prescription service (EPS) through to March 2021. This included a review of the use of FP10 MDA prescriptions. This exercise identified several other higher priority EPS related developments at that time. Significant technological development is required, both centrally and by system vendors, for electronic FP10 MDA prescriptions to be processed legally and safely.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 July 2020 to Question 71722 on Methadone: Prescriptions, what plans he has to authorise requests from NHS and voluntary sector providers to electronically prescribe FP10 MDA opioid substitution therapy.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 21 July 2020 to Question 71722 on Methadone: Prescriptions, what plans he has to authorise requests from NHS and voluntary sector providers to electronically prescribe FP10 MDA opioid substitution therapy.
There has already been unprecedented growth in the use and availability of electronic prescribing across the system. However, the Government wants to go further and enable as many prescriptions as possible can be sent electronically. The aim to increase the use of electronic prescribing builds on work already ongoing throughout the National Health Service, where more than 6,000 general practitioners are now able to use the Electronic Prescription Service (EPS).
However, significant technological development is required, both centrally and by system vendors, for electronic FP10 MDA prescriptions to be processed legally and safely.
In 2018 NHS Digital undertook a prioritisation exercise to identify future enhancements and improvements to the EPS through to March 2021. This included a review of the use of FP10 MDA prescriptions. This exercise identified several other higher priority EPS related developments at that time.
A recent review by NHS Digital looking at the availability of the Electronic Prescription Service (EPS) in light of the National Health Service’s COVID-19 response, considered that prescribers could not use EPS for FP10 MDA prescriptions. While this review resulted in work being initiated to accelerate technical...
A recent review by NHS Digital looking at the availability of the Electronic Prescription Service (EPS) in light of the National Health Service’s COVID-19 response, considered that prescribers could not use EPS for FP10 MDA prescriptions. While this review resulted in work being initiated to accelerate technical...
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 July 2020 to Question 61461 on Methadone: Prescriptions, what assessment his Department has made of the capacity of prescribers to safely electronically prescribe FP10 MDA opioid substitution therapy in England.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 July 2020 to Question 61461 on Methadone: Prescriptions, what assessment his Department has made of the capacity of prescribers to safely electronically prescribe FP10 MDA opioid substitution therapy in England.
The Government has announced that from Friday 24 July, members of the public must wear a face covering when visiting a shop or supermarket in England. Guidance on how to wear and remove a face covering was published online on 14 July. In addition, the Government is running a major proactive communications campaign on face coverings to alert the public where they are now required to wear face coverings and educate the public on how to correctly wear one.
Legitimate reasons for not wearing a mask include if they are travelling with or providing assistance to someone who relies on lip reading to communicate or if they are not able to put on, wear or remove a face covering because of a physical or mental illness or impairment, or disability. People will be able to remove their face covering if speaking with people who rely on lip reading, facial expressions or clear sound to communicate.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 July 2020 to Question 61461 on Methadone: Prescriptions, what discussion his department has had with Public Health England on NHS and voluntary sector provider requests to electronically prescribe FP10 MDA opioid substitution therapy.
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 8 July 2020 to Question 61461 on Methadone: Prescriptions, what discussion his department has had with Public Health England on NHS and voluntary sector provider requests to electronically prescribe FP10 MDA opioid substitution therapy.
Requests from both the National Health Service and the voluntary sector to electronically prescribe FP10 MDA prescriptions have been raised as part of routine discussions between the Department and Public Health England.
To ask the Secretary of State for Health and Social Care, what plans his Department has to enable the use of electronic FP 10 MDA prescriptions during the covid-19 outbreak.
To ask the Secretary of State for Health and Social Care, what plans his Department has to enable the use of electronic FP 10 MDA prescriptions during the covid-19 outbreak.
In 2018 NHS Digital undertook a prioritisation exercise to identify future enhancements and improvements to the electronic prescription service (EPS) through to March 2021. This included a review of the use of FP10 MDA prescriptions. This exercise identified several other higher priority developments to EPS that were required at that time.
More recently work to review gaps in the EPS as part of the NHS COVID-19 response has resulted in some work being initiated to accelerate technical developments that will be required to support both this and other immediate concerns. This work has commenced but does not currently include EPS support for FP10 MDA prescription use due to the technical changes required. This is a highly complex area and requires significant development both centrally and by system vendors.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the use of electronic prescription for FP10 MDA prescriptions.
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the use of electronic prescription for FP10 MDA prescriptions.
In 2018 NHS Digital undertook a prioritisation exercise to identify future enhancements and improvements to the electronic prescription service (EPS) through to March 2021. This included a review of the use of FP10 MDA prescriptions. This exercise identified several other higher priority developments to EPS that were required at that time.
More recently work to review gaps in the EPS as part of the NHS COVID-19 response has resulted in some work being initiated to accelerate technical developments that will be required to support both this and other immediate concerns. This work has commenced but does not currently include EPS support for FP10 MDA prescription use due to the technical changes required. This is a highly complex area and requires significant development both centrally and by system vendors.
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of supply of (a) buprenorphine, (b) methadone and (c) naltrexone during the covid-19 outbreak.
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the adequacy of supply of (a) buprenorphine, (b) methadone and (c) naltrexone during the covid-19 outbreak.
As part of our concerted national efforts to respond to the COVID-19 outbreak, we are doing everything we can to ensure patients continue to have access safe and effective medicines. Supplies of buprenorphine, methadone and naltrexone continue to remain available.
The Department has well-established procedures to deal with medicine shortages and is working closely with industry, the National Health Service and others in the supply chain to reduce the likelihood of future shortages.
The Department shares regular information about impending supply issues and management plans with the NHS via networks in primary and secondary care and will liaise with relevant patient groups about issues affecting specific medicines, medical devices and equipment.
To ask Her Majesty's Government what was the purchase price of methadone, per unit, paid by the NHS in England in (1) 2005, (2) 2010, (3) 2015, and (4) 2019.
To ask Her Majesty's Government what was the purchase price of methadone, per unit, paid by the NHS in England in (1) 2005, (2) 2010, (3) 2015, and (4) 2019.
It has not proved possible to respond to this question in the time available before Dissolution. Ministers will correspond directly with the Member.
To ask Her Majesty's Government what is the average annual cost per person of methadone (1) treatment, and (2) supervision.
To ask Her Majesty's Government what is the average annual cost per person of methadone (1) treatment, and (2) supervision.
It has not proved possible to respond to this question in the time available before Dissolution. Ministers will correspond directly with the Member.
To ask Her Majesty's Government whether they have assessed the value for money that the methadone programme in England represents; if so, what was the outcome of any such assessment; and if not, why not.
To ask Her Majesty's Government whether they have assessed the value for money that the methadone programme in England represents; if so, what was the outcome of any such assessment; and if not, why not.
It has not proved possible to respond to this question in the time available before Dissolution. Ministers will correspond directly with the Member.
To ask Her Majesty's Government what plans they have to divert funding currently used for methadone treatment to initiatives to support people to abstain from opiates.
To ask Her Majesty's Government what plans they have to divert funding currently used for methadone treatment to initiatives to support people to abstain from opiates.
It has not proved possible to respond to this question in the time available before Dissolution. Ministers will correspond directly with the Member.
To ask Her Majesty's Government, further to the answer by Baroness Blackwood of North Oxford on 28 October (HL Deb, col 772), why data on the costs of the supply of methadone are not collected centrally; and what data are available on the number of patients using methadone in different regions of England.
To ask Her Majesty's Government, further to the answer by Baroness Blackwood of North Oxford on 28 October (HL Deb, col 772), why data on the costs of the supply of methadone are not collected centrally; and what data are available on the number of patients using methadone in different regions of England.
The Government does not collect detailed data like the costs of supplying specific drugs, such as methadone.
Public Health England collects data from the National Drug Treatment Monitoring System on the number of people in treatment for opiates who are receiving a pharmacological intervention. Most of these people received prescriptions as part of opiate substitution therapy, for which methadone is the most commonly prescribed medication.
My Lords, methadone is a cost-effective and evidence-based opioid substitution treatment. The National Institute for Health and Care Excellence has published several pieces of guidance on drug treatment. It recommends opioid substitute treatment with either methadone or buprenorphine, delivered alongside psychosocial treatment, as the front-line treatment for heroin dependency. There are no plans to undertake any further review.
My Lords, methadone is a cost-effective and evidence-based opioid substitution treatment. The National Institute for Health and Care Excellence has published several pieces of guidance on drug treatment. It recommends opioid substitute treatment with either methadone or buprenorphine, delivered alongside psychosocial treatment, as the front-line treatment for heroin dependency. There are no plans to undertake any further review.
To ask Her Majesty’s Government what plans they have to assess the regulation, and the general effectiveness, of methadone.
My Lords, I am grateful to the Minister for that reply. I am disappointed that the Government are not prepared to undertake a review. I do not want methadone treatment to end, but I believe that the cost is now becoming astronomical and have sent the Minister questions about this previously. People in the industry say that it now costs £1 billion a year, yet an increasing number of people are dying from methadone and a shortage of resourcing for support and advice. We are going nowhere. They are
parked in a cul-de-sac. Should we not take a look at what alternatives may be available, where that kind of money could be put to better use and give people hope, rather than just abandon them?
My Lords, I am grateful to the Minister for that reply. I am disappointed that the Government are not prepared to undertake a review. I do not want methadone treatment to end, but I believe that the cost is now becoming astronomical and have sent the Minister questions about this previously. People in the industry say that it now costs £1 billion a year, yet an increasing number of people are dying from methadone and a shortage of resourcing for support and advice. We are going nowhere. They are
parked in a cul-de-sac. Should we not take a look at what alternatives may be available, where that kind of money could be put to better use and give people hope, rather than just abandon them?
I thank the noble Lord for his question. He will know that the DHSC does not collect data on the costs of supply of methadone centrally, as he has asked this question. However, I reassure him that Public Health England carried out an evidence review in 2017 on the effectiveness of drug treatment across the UK, which found that our outcomes are as good as or better than those internationally, including on effectiveness and value for money. However, we recognise the challenge of drug deaths and drug treatment across the UK and the challenge to local authorities. There will be an effective review of drugs policy, which will include Carol Black’s review of drugs.
I thank the noble Lord for his question. He will know that the DHSC does not collect data on the costs of supply of methadone centrally, as he has asked this question. However, I reassure him that Public Health England carried out an evidence review in 2017 on the effectiveness of drug treatment across the UK, which found that our outcomes are as good as or better than those internationally, including on effectiveness and value for money. However, we recognise the challenge of drug deaths and drug treatment across the UK and the challenge to local authorities. There will be an effective review of drugs policy, which will include Carol Black’s review of drugs.
I thank the noble Lord for his question. He will know that the DHSC does not collect data on the costs of supply of methadone centrally, as he has asked this question. However, I reassure him that Public Health England carried out an evidence review in 2017 on the effectiveness of drug treatment across the UK, which found that our outcomes are as good as or better than those internationally, including on effectiveness and value for money. However, we recognise the challenge of drug deaths and drug treatment across the UK and the challenge to local authorities. There will be an effective review of drugs policy, which will include Carol Black’s review of drugs.
My Lords, I am grateful to the Minister for that reply. I am disappointed that the Government are not prepared to undertake a review. I do not want methadone treatment to end, but I believe that the cost is now becoming astronomical and have sent the Minister questions about this previously. People in the industry say that it now costs £1 billion a year, yet an increasing number of people are dying from methadone and a shortage of resourcing for support and advice. We are going nowhere. They are
parked in a cul-de-sac. Should we not take a look at what alternatives may be available, where that kind of money could be put to better use and give people hope, rather than just abandon them?
My Lords, what consideration has been given to extending the Swiss model of heroin-assisted treatment, with addicts attending clinics under supervision and injecting safely, given that there is clear evidence of the success of this model in improving the health of addicts and reducing both the number of overdoses and levels of crime?
My Lords, what consideration has been given to extending the Swiss model of heroin-assisted treatment, with addicts attending clinics under supervision and injecting safely, given that there is clear evidence of the success of this model in improving the health of addicts and reducing both the number of overdoses and levels of crime?
Heroin-assisted treatment can be an effective way of treating individuals for whom other opioid substitutes have not been effective. It is open to local areas under the existing legal framework, but given that funding decisions on drug and alcohol treatment have been devolved, it is for them to decide whether to commission HAT services based on their assessment of local need.
Heroin-assisted treatment can be an effective way of treating individuals for whom other opioid substitutes have not been effective. It is open to local areas under the existing legal framework, but given that funding decisions on drug and alcohol treatment have been devolved, it is for them to decide whether to commission HAT services based on their assessment of local need.
Heroin-assisted treatment can be an effective way of treating individuals for whom other opioid substitutes have not been effective. It is open to local areas under the existing legal framework, but given that funding decisions on drug and alcohol treatment have been devolved, it is for them to decide whether to commission HAT services based on their assessment of local need.
My Lords, what consideration has been given to extending the Swiss model of heroin-assisted treatment, with addicts attending clinics under supervision and injecting safely, given that there is clear evidence of the success of this model in improving the health of addicts and reducing both the number of overdoses and levels of crime?
My Lords, are the Government seriously suggesting that they could be spending £1 billion but do not actually know whether they are?
My Lords, are the Government seriously suggesting that they could be spending £1 billion but do not actually know whether they are?
No, the Government are suggesting that a PHE review in 2017 found that drug and alcohol treatment services are currently as good as or better than international comparators. They are cost-effective and the outcomes are good. However, we recognise that the number of deaths at the moment is too high, which is why the Home Office has commissioned a review of drugs policy by Dame Carol Black, and there will be a summit in Glasgow before the end of the year to find out what more can be done to improve these services.